KYAN Technologies: Difference between revisions
No edit summary |
|||
| Line 13: | Line 13: | ||
==Technology== | ==Technology== | ||
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ | KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types. | ||
The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>. | |||
==Traction== | ==Traction== | ||
| Line 22: | Line 24: | ||
==Funding== | ==Funding== | ||
KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>.{{Startup/Funding history}} | |||
== See also == | == See also == | ||
Revision as of 23:14, 20 December 2025
|
This article is a draft
It is still in development and may change significantly as it is expanded. If you like to contribute to this work, please reach out to the draft's author.
|
 | |
| Status | Active |
|---|---|
| Website | https://kyantechnologies.com/ |
| Vertical(s) | Medtech, Biotechnology |
| Latest Funding Round | Pre-Series A |
| Year founded | 2016 |
| Headquarters | Singapore |
| Technology Readiness Level | Deployment (TRL 7-8) |
KYAN Technologies is a Singapore-based startup that is developing a platform for precision medicine for both treatment and drug development.
Technology
KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy[1] across 20+ different cancer types.
The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models[2].
Traction
List notable customers or partnerships here. Awards should not be listed here, but under "Accolades" instead
Accolades
List awards received by the startup here.
Funding
KYAN Technologies raised US$5 million in pre-Series A funding from lead investor Altara Ventures in October 2022[3].
| Funding History | |
|---|---|
| Investor | Round |
| Altara Ventures | Pre-Series A |
| Seeds Capital | Pre-Series A |
| K3 Ventures | Pre-Series A |
Note: This list is community-maintained and may be incomplete or contain inaccuracies.
See also
- List any other pages directly relevant to KYAN Technologies
References
- ↑ "Optim.AI™ for Clinicians". KYAN Technologies. Retrieved 2025-12-20.
- ↑ "Translational Biobank". KYAN Technologies. Retrieved 2025-12-20.
- ↑ Chong, Jinn Xiung. "Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round".
{{cite web}}: CS1 maint: url-status (link)